Published in Trends Pharmacol Sci on June 25, 2010
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Regulation of N-methyl-D-aspartate receptors by disrupted-in-schizophrenia-1. Biol Psychiatry (2013) 1.52
Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. EMBO J (2011) 1.40
Recent advances in quantitative neuroproteomics. Methods (2013) 1.23
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci (2013) 1.12
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci (2012) 1.12
The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology (2010) 1.09
The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends Mol Med (2011) 1.08
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem (2011) 1.03
Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology (2013) 0.96
The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiol Dis (2011) 0.95
Developmental origins of brain disorders: roles for dopamine. Front Cell Neurosci (2013) 0.94
Association study of the KCNJ3 gene as a susceptibility candidate for schizophrenia in the Chinese population. Hum Genet (2011) 0.93
Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov (2016) 0.88
Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia. Neurobiol Learn Mem (2015) 0.83
Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology (Berl) (2013) 0.82
Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother (2012) 0.81
Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmacol (2012) 0.80
Bridging the Gap between Genes and Language Deficits in Schizophrenia: An Oscillopathic Approach. Front Hum Neurosci (2016) 0.79
Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Comput Biol (2015) 0.79
MET and AKT genetic influence on facial emotion perception. PLoS One (2012) 0.79
Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol (2017) 0.79
Long-term effects of maternal deprivation on cholinergic system in rat brain. Biomed Res Int (2014) 0.78
Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One (2015) 0.77
Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. Front Cell Neurosci (2013) 0.76
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol (2016) 0.76
Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect (2014) 0.76
Effect of C-Terminal S-Palmitoylation on D2 Dopamine Receptor Trafficking and Stability. PLoS One (2015) 0.76
Dopamine D2 receptor-mediated Akt/PKB signalling: initiation by the D2S receptor and role in quinpirole-induced behavioural activation. ASN Neuro (2012) 0.76
Imaging the Insertion of Superecliptic pHluorin-Labeled Dopamine D2 Receptor Using Total Internal Reflection Fluorescence Microscopy. Curr Protoc Neurosci (2015) 0.75
Association of PDE4B Polymorphisms with Susceptibility to Schizophrenia: A Meta-Analysis of Case-Control Studies. PLoS One (2016) 0.75
Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective. Int J Health Sci (Qassim) (2016) 0.75
The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia. Mol Cell Ther (2016) 0.75
Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci (2017) 0.75
Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders. Int J Mol Sci (2017) 0.75
The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 21.70
Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet (2008) 10.19
Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet (2002) 7.40
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
PSD-95 involvement in maturation of excitatory synapses. Science (2000) 6.15
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell (2009) 5.34
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci (2008) 4.91
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci (2003) 4.86
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet (2004) 4.71
Identification of PSD-95 palmitoylating enzymes. Neuron (2004) 4.37
Association within a family of a balanced autosomal translocation with major mental illness. Lancet (1990) 3.94
PI3K/Akt: getting it right matters. Oncogene (2008) 3.91
A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol (2005) 3.89
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 3.70
A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet (2002) 3.52
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry (2008) 3.51
The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase. J Cell Biol (2002) 3.48
The DISC locus in psychiatric illness. Mol Psychiatry (2007) 3.46
Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry (2006) 3.33
Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet (2009) 3.25
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci (2008) 3.22
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature (2010) 2.92
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics (2003) 2.88
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther (2004) 2.83
Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet (2004) 2.77
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans (2007) 2.70
Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res (2008) 2.67
Catching up on schizophrenia: natural history and neurobiology. Neuron (2000) 2.63
Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci (2009) 2.55
The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1988) 2.51
A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron (2001) 2.48
DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet (2003) 2.39
A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci U S A (2008) 2.37
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry (2008) 2.33
Protein palmitoylation: a regulator of neuronal development and function. Nat Rev Neurosci (2002) 2.32
Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry (2006) 2.32
Exacerbation of schizophrenia by varenicline. Am J Psychiatry (2007) 2.27
The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22
A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci (2006) 2.16
Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci (2000) 2.13
A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet (2003) 2.11
Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res (2001) 2.05
Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem (2009) 1.97
Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci (2008) 1.92
Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A (2002) 1.92
Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci (2005) 1.91
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci (2008) 1.80
DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc Natl Acad Sci U S A (2009) 1.76
The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res (2004) 1.74
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry (2007) 1.73
Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci U S A (2000) 1.72
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) (2004) 1.69
The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry (2007) 1.68
The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet (1999) 1.67
Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Mol Cell Neurosci (2004) 1.62
Presynaptic type III neuregulin1-ErbB signaling targets {alpha}7 nicotinic acetylcholine receptors to axons. J Cell Biol (2008) 1.61
Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A (2002) 1.60
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther (2006) 1.60
The role of GSK-3 in synaptic plasticity. Br J Pharmacol (2008) 1.52
Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry (2008) 1.51
Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry (2006) 1.49
Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb Cortex (2008) 1.42
Activity-independent regulation of dendrite patterning by postsynaptic density protein PSD-95. J Neurosci (2006) 1.41
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38
Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther (2003) 1.38
SZGR: a comprehensive schizophrenia gene resource. Mol Psychiatry (2010) 1.36
Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci (2009) 1.32
AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry (2007) 1.30
The role of obstetric events in schizophrenia. Schizophr Bull (2005) 1.26
Animal models for the negative symptoms of schizophrenia. Behav Pharmacol (2000) 1.22
Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biol Psychiatry (2004) 1.18
Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry (2008) 1.17
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev (2005) 1.16
Follow-up report of potential linkage for schizophrenia on chromosome 22q: Part 3. Am J Med Genet (1995) 1.12
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 1.11
Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry (2007) 1.06
Association of 5' end neuregulin-1 (NRG1) gene variation with subcortical medial frontal microstructure in humans. Neuroimage (2008) 1.04
Dissecting the genetic complexity of schizophrenia. Mol Psychiatry (1997) 1.04
The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res (1996) 1.03
Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry (2008) 1.03
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem (2008) 1.03
Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat (2009) 0.99
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
Animal models of gene-environment interactions in schizophrenia. Behav Brain Res (2009) 0.98
A family-based association study of schizophrenia with polymorphisms at three candidate genes. Neurosci Lett (2005) 0.98
Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry (2007) 0.97
Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol (2009) 0.96
Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population. Am J Med Genet B Neuropsychiatr Genet (2004) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol (2009) 0.91
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell (2008) 4.29
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol (2006) 3.23
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J (2008) 2.99
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol (2011) 2.99
Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol (2009) 2.98
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem (2002) 2.87
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Cyanine fluorophore derivatives with enhanced photostability. Nat Methods (2011) 2.85
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem (2002) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 2.72
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature (2010) 2.41
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
Monitoring the function of membrane transport proteins in detergent-solubilized form. Proc Natl Acad Sci U S A (2007) 2.27
The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol (2002) 2.27
Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature (2007) 2.25
Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proc Natl Acad Sci U S A (2009) 2.25
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nat Struct Mol Biol (2010) 2.20
Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature (2011) 2.18
The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci U S A (2004) 2.10
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
An intracellular interaction network regulates conformational transitions in the dopamine transporter. J Biol Chem (2008) 2.07
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv (2009) 2.05
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter:sodium symporter from Fusobacterium nucleatum. J Biol Chem (2006) 2.01
Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron (2006) 2.00
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A (2005) 1.98
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol (2004) 1.94
Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem (2012) 1.87
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Components and correlates of family burden in schizophrenia. Psychiatr Serv (2006) 1.81
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry (2010) 1.79
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry (2009) 1.71
Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters. J Biol Chem (2003) 1.70
Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem (2003) 1.69
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry (2005) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
PI 3-kinase regulation of dopamine uptake. J Neurochem (2002) 1.64
Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci (2003) 1.63
Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry (2008) 1.62
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res (2009) 1.54
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem (2008) 1.51
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry (2008) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49